FDA Approves Bristol Myers Squibb’s Zenbexus, First CELMoD for Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s iberdomide (Zenbexus), the company’s first approved CELMoD, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for multiple myeloma patients who have received at least one…
